We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Microsaic Systems Plc | LSE:MSYS | London | Ordinary Share | GB00BMWC8365 | ORD GBP0.00001 |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-0.025 | -2.50% | 0.975 | 0.95 | 1.00 | 1.00 | 0.975 | 1.00 | 2,186,520 | 09:31:47 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Electronic Components, Nec | 1.57M | -2.29M | -0.0128 | -0.76 | 1.74M |
Date | Subject | Author | Discuss |
---|---|---|---|
08/3/2018 12:15 | A game changer ahead on disclosure of Microsaic's global biopharma partner on successful technology trials and already validated by their partner's BIG pharma end users and on-going integration into their partner's product equipment..Gla holders..On and Up!!!;-) Q1: Microsaic recently announced the signing of a research agreement with a global partner in biopharma, can you tell us a little bit more about that? A1: Yes, absolutely so Ive got to say that we are under strict NDA in this particular case but what I can do is give you some context. Earlier in the year we successfully completed a significant joint feasibility phase to show dedicated at-line mass spec can assess the quality of biologics during the manufacture. I think perhaps the most important aspect of that phase was that we had substantial end-user validation from big pharma and just to say that these are end-users whom our partner has very good global reach. What this new phase is it will bring more end-user validation to the approach, but I think the exciting deliverable is that we'll be able to provide a lot more technical integration with the partners product. So, should this activity be successful, it will take us into the second half of 2018 and then that will proceed a period of productisation. As I said, I can't give any details yet about the size and timeline for commercialisation, but the opportunity is significant to us, to Microsaic, and delivery is proportionate, I would say, to our timescales. | moneymunch | |
08/3/2018 12:15 | MICOSAIC is Hitting many Radars once more. Glen Tracey is BELIEVING and Followers are coming. Strong Buy says "The EGREGORE". OK? | the egregore | |
08/3/2018 11:54 | A multi-bag in the making from this bargain low share price ..Gla holders:-) Q5: So, what does your strategy as a group look like for the next 12 months? A5: We are going to be launching fully, what we call, the 4500 product this year so that means that we can not only measure small molecules but also metabolites, peptides and small proteins and this is important to us because it enables us to talk to many more, and wider set, of OEM’s. We do also have a very existing tool-less technology and development and we feel this is truly unique and we think it’s going to be revolutionary in product maintenance, it will reduce maintenance from typically hours down to minutes. However, our key focus, as I said, is really on bioprocessing and we are targeting to have that concept ready towards the end of 2018. On the commercial side, we are encouraged by progress since taking on the position of having more OEM partnerships and I remain hopeful to see a proportion of these converting this year, particularly in the second half. | moneymunch | |
08/3/2018 11:54 | A multi-bag in the making from this bargain low share price ..Gla holders:-) Q5: So, what does your strategy as a group look like for the next 12 months? A5: We are going to be launching fully, what we call, the 4500 product this year so that means that we can not only measure small molecules but also metabolites, peptides and small proteins and this is important to us because it enables us to talk to many more, and wider set, of OEM’s. We do also have a very existing tool-less technology and development and we feel this is truly unique and we think it’s going to be revolutionary in product maintenance, it will reduce maintenance from typically hours down to minutes. However, our key focus, as I said, is really on bioprocessing and we are targeting to have that concept ready towards the end of 2018. On the commercial side, we are encouraged by progress since taking on the position of having more OEM partnerships and I remain hopeful to see a proportion of these converting this year, particularly in the second half. | moneymunch | |
08/3/2018 11:09 | You arent going anywhere sunshine | bobmonkeyhouse | |
08/3/2018 10:36 | Lemeri coming to the Costa Del Sol....Ha ha ha:-) | moneymunch | |
08/3/2018 10:32 | Lol.... thanks Eikel, that narrows it down...Tick Tock:-) | moneymunch | |
08/3/2018 10:30 | I am Dutch not canadian you moron | bobmonkeyhouse | |
08/3/2018 08:52 | MoneyMunch To be fair you do have past form of a blatant RAMPER from UKOG threads, looks like your at it again on this BB. Beware Money Munch , YES your hard earned WILL be munched ! | boxerdogz | |
08/3/2018 08:41 | monkeynuts I think you need to watch the ukog thread now the legal action is being mentioned against you. LOL | bobmonkeyhouse | |
08/3/2018 08:03 | Lol... now there's a thought!!! Gl ;-) | moneymunch | |
08/3/2018 07:11 | Unless of course you are all the same person. | bagpuss67 | |
08/3/2018 07:10 | Money munch. Why do you keep up this pointless exchange. This happens on other threads: just stop posting and the kids will stop posting from their bedrooms in response. Let the thread die and use another site such as LSE. If the company starts to make progress then the people with a real interest will return and start posting. | bagpuss67 | |
07/3/2018 19:39 | I've still got that botty cream monkeynuts. I'll pay postage since your ball deep in this :) | stephen2010 | |
07/3/2018 17:11 | Lemeri coming your way....Ha ha ha:-) | moneymunch |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions